Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to ...

▎药明康德内容团队编辑  皮肤没长什么东西，却莫名其妙地反复瘙痒，在夜晚格外严重，甚至痒得睡不着觉；身上挠出一道道印子，用了很多护肤品、止痒药也没什么效果……对于很多肝胆疾病导致胆汁淤积的患者来说，这样难以忍受的全身性瘙痒常常发生，极大地影响了生活质 ...

Mirum Pharmaceuticals ( (MIRM) ) has released its Q3 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its ...

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...

We've also made excellent progress with our pipeline. The list of that has been granted breakthrough designation for ...

(Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to volixibat as a potential treatment for cholestatic pruritus in ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Report Ocean has published a new report on the Pruritus Therapeutics Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...

AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...